| Name | Title | Contact Details |
|---|
BENESIGHT is a Pueblo, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Idenix Pharmaceuticals, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Idenix Pharmaceuticals, Inc. is based in Cambridge, MA. You can find more information on Idenix Pharmaceuticals, Inc. at www.idenix.com
Crowne Management is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Monroeville, AL. To find more information about Crowne Management, please visit www.crownemanagement.com
You have many choices when it comes to taking care of the precious gift of your health and that of your loved ones. For over ninety years, Baptist Health System has been taking care of our communities. The reason to choose Baptist today? It comes down to nationally recognized, high-quality care driven by our purpose, to Honor God and Others. It`s the Baptist network of doctors and healthcare professionals that can now work together to coordinate your care because of innovative technology such as electronic medical records. It`s the focus on whole person healing, prevention and the experience of patients and families trusting us with their care.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.